SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-15-271844
Filing Date
2015-07-31
Accepted
2015-07-31 07:01:06
Documents
11
Period of Report
2015-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d937928d10q.htm 10-Q 721875
2 EX-10.63 d937928dex1063.htm EX-10.63 34303
3 EX-31.1 d937928dex311.htm EX-31.1 9164
4 EX-31.2 d937928dex312.htm EX-31.2 9194
5 EX-32.1 d937928dex321.htm EX-32.1 5509
  Complete submission text file 0001193125-15-271844.txt   4737314

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT vnda-20150630.xml EX-101.INS 706108
7 XBRL TAXONOMY EXTENSION SCHEMA vnda-20150630.xsd EX-101.SCH 62728
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vnda-20150630_cal.xml EX-101.CAL 79263
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20150630_def.xml EX-101.DEF 376822
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20150630_lab.xml EX-101.LAB 459400
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20150630_pre.xml EX-101.PRE 448071
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 151017810
SIC: 2834 Pharmaceutical Preparations